BPC-157 and Gut Health: What We Know—and What We Don’t

An FDA advisory committee has recommended allowing BPC-157 and five other peptides to be used in certain compounded medications. Here is what that decision means—and why it is not the same as FDA approval.

Peptides are having a moment. 

Once discussed mainly in research settings, they are now appearing in podcasts, wellness clinics, social media feeds and conversations between patients and their health practitioners. One peptide in particular—BPC-157—is frequently promoted for healing injuries, reducing inflammation and repairing the gut.

People ask me about it often, and I understand why. When you have dealt with persistent digestive symptoms, inflammation or an intestinal condition, something described as a “gut-healing peptide” naturally gets your attention.

BPC-157 is intriguing. It may even become a useful clinical tool. But the public enthusiasm surrounding it has moved much faster than the human research.

Here is what we currently know, what we do not know and what the FDA’s recent advisory decision actually means.

What is BPC-157?

Peptides are short chains of amino acids—the same building blocks that make up larger proteins. Some peptides have become well-established medications. Insulin and certain GLP-1 medications are examples, but they have also undergone extensive clinical testing and regulatory review.

BPC-157 is a synthetic peptide made of 15 amino acids. It was developed from a peptide sequence associated with a protective compound originally isolated from human gastric juice. Much of the excitement surrounding BPC-157 comes from laboratory and animal studies exploring its possible effects on tissue protection, inflammation and wound healing.  

In animal models, researchers have reported effects involving gastrointestinal injuries, colonic fistulas and other damaged tissues. Proposed mechanisms include changes in inflammatory signaling, blood-vessel formation, nitric oxide activity and growth-factor pathways.

However, the FDA’s scientific review noted that BPC-157’s molecular targets have not been identified, its mechanisms remain poorly understood and clear dose-response relationships have not been established. Promising results in cells, rats or other animals are an important starting point—but they do not tell us whether the same treatment will be safe and effective in humans.  

Why is BPC-157 in the news now? 

During a two-day meeting on July 23–24, 2026, the FDA’s Pharmacy Compounding Advisory Committee reviewed seven peptides for possible inclusion on the 503A Bulks List. This is a list of ingredients that may be used by certain state-licensed pharmacies and physicians to prepare individualized compounded medications when federal requirements are met.

The committee recommended that six peptides—BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax—be placed on the list. It did not recommend adding emideltide, also known as DSIP. The vote on BPC-157 was narrow: eight members voted in favor, six voted against and one abstained.  

This is a meaningful regulatory development, but it is easy to misinterpret.

The committee did not FDA-approve BPC-157—or any of the other peptides.

The recommendations are advisory and nonbinding. The FDA must still decide whether to accept them and formally add the substances to the 503A Bulks List. Even if BPC-157 is eventually added, compounded preparations containing it would not become FDA-approved drugs.  

The committee’s vote also did not establish that BPC-157 is effective for every condition associated with it online. For this review, the FDA evaluated BPC-157 specifically for ulcerative colitis. It did not evaluate it as a universal treatment for IBS, bloating, reflux, food sensitivities, intestinal permeability or general “gut repair.”  

Some committee members supported placing BPC-157 on the list because they believed access through licensed compounding pharmacies could be safer than leaving consumers to purchase unregulated products through the gray market. Members who opposed the recommendation emphasized the limited human evidence and the risk that consumers would interpret inclusion on the compounding list as proof of FDA approval, safety or effectiveness.

Compounded does not mean FDA-approved

Compounded medications can serve an important purpose when a patient has a medical need that cannot be met by a commercially available, FDA-approved product.

However, the FDA does not review compounded medications for safety, effectiveness or quality before they are marketed in the same way it evaluates an approved drug. Product formulation, purity, potency, storage and consistency still matter—particularly with peptides, which may be vulnerable to degradation, aggregation and impurities.  

In other words, allowing a substance to be compounded is not the same as concluding:

• It works for a particular condition.
• Its benefits outweigh its risks.
• Every formulation or route of administration is equivalent.
• It is appropriate for anyone who wants to “heal their gut.”

That distinction is important because BPC-157 is already marketed online for a wide range of concerns, including IBS, inflammatory bowel disease, stomach ulcers, intestinal permeability and general digestive support.

The human evidence does not currently support all of those claims.

What does the human research show?

For its recent review, the FDA specifically evaluated BPC-157 for ulcerative colitis. Although it had also been nominated for Crohn’s disease, celiac disease and tendonitis, the agency reported that it did not have enough information or relevant clinical studies to evaluate those additional uses.  

The most relevant ulcerative-colitis study included 53 participants with mild-to-moderate disease. Participants received either BPC-157 or a placebo once daily for two weeks.

There are several important limitations:

The treatment was given as a rectal enema. It was not an oral capsule, nasal spray, transdermal cream or subcutaneous injection—the routes people may be offered in current wellness settings.

The study was available only as a meeting abstract rather than a full published report. Important information about participant selection, statistical methods, outcome measurements and follow-up was missing. The FDA concluded that the available data were inadequate to establish the treatment’s safety or effectiveness for ulcerative colitis.  

The FDA identified five small human studies involving several different health concerns and routes of administration. No serious adverse events appeared to have been reported in those studies, but the trials were short, included very few participants and provided limited safety information. The agency concluded that there was not enough clinical evidence to characterize BPC-157’s safety profile—especially with repeated or long-term use.  

It is therefore too early to conclude that BPC-157 is a proven treatment for ulcerative colitis—and the evidence is even thinner for broad claims involving IBS, bloating, food reactions, reflux, “leaky gut” or general microbiome repair.

The questions I would ask before using BPC-157

I am not opposed to emerging therapies. Good healthcare evolves as better research becomes available. But a new intervention should come with more questions—not fewer.

Before trying BPC-157 or another peptide, ask:

• What specific condition or problem are we trying to treat?
• Is there human research supporting this exact use, dosage and route of administration?
• Where is the product coming from, and how is its identity and purity verified?
• What are the known risks, and what remains unknown?
• How will benefits, side effects and interactions be monitored?
• Are we also addressing the factors that may be interfering with healing?

Persistent gut symptoms can involve much more than an injured intestinal lining. Depending on the person, the larger picture may include microbiome disruption, digestive insufficiency, altered motility, infections or overgrowth, medication effects, chronic stress, insufficient nutrition, immune activity or ongoing inflammatory triggers.

A peptide—assuming it proves helpful—would still be one possible tool within that larger picture. It would not automatically identify or resolve the reason someone’s gut is struggling.

Promising is not the same as proven

BPC-157 is worth studying. The laboratory and animal research is interesting, and the committee’s recommendation may eventually create a more regulated, prescription-based pathway for accessing compounded BPC-157. Whether the FDA will accept that recommendation—and whether broader access will lead to better human research—remains to be seen.

But we should not confuse increased availability with established evidence.

For now, the most accurate conclusion is this: BPC-157 may have therapeutic potential, but we do not yet have enough high-quality human research to call it a proven or broadly safe gut-healing treatment.

You can remain curious without being swept up in the marketing. And when your symptoms are persistent, the best place to begin is not necessarily with the newest treatment. It is with a clearer understanding of what is happening in your body and what it may need to heal.

Ready to stop guessing about your gut?

When bloating, reflux, constipation, loose stools, food reactions or seemingly unrelated symptoms continue despite everything you have tried, a personalized gut-health approach can help connect the dots.

Book a Gut Clarity Call to discuss what you are experiencing, what you have already tried and which next steps may make sense for you.

Regulatory information is current as of July 28, 2026. The FDA has not yet issued a final decision on the advisory committee’s recommendations.